Franklin Resources’s KalVista Pharmaceuticals KALV Stock Holding History

Franklin Resources’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,239,731	Closed	-$18.3M	–	2417
2022 Q1	$18.3M	Sell	1,239,731 -12,411	-1%	-$178K	0.01%	878
2021 Q4	$16.6M	Sell	1,252,142 -148,317	-11%	-$2.36M	0.01%	938
2021 Q3	$24.4M	Sell	1,400,459 -55,334	-4%	-$1.12M	0.01%	846
2021 Q2	$34.9M	Buy	1,455,793 +168,132	+13%	+$4.4M	0.01%	743
2021 Q1	$33.1M	Buy	1,287,661 +887,951	+222%	+$23.3M	0.01%	729
2020 Q4	$7.59M	Buy	399,710 +165,810	+71%	+$2.84M	﹤0.01%	1011
2020 Q3	$2.94M	Hold	233,900	–	–	﹤0.01%	1143
2020 Q2	$2.96M	Hold	233,900	–	–	﹤0.01%	1081
2020 Q1	$1.79M	Sell	233,900 -49,600	-17%	-$669K	﹤0.01%	1114
2019 Q4	$5.05M	Buy	+283,500	New	+$3.7M	﹤0.01%	1013
2016 Q1	–	Sell	-103,357	Closed	-$5.24M	–	1538
2015 Q4	$5.24M	Hold	103,357	–	–	﹤0.01%	1121
2015 Q3	$5.17M	Sell	103,357 -5,507	-5%	-$469K	﹤0.01%	1137
2015 Q2	$10.9M	Buy	+108,864	New	+$10.8M	﹤0.01%	1023

Other funds holding KALV

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Franklin Resources's KALV Position: Q2 2022 in Review

Franklin Resources sold out of KalVista Pharmaceuticals (KALV) in Q2 2022, closing a stake of 1,239,731 shares — an estimated $18.3M sold.

Franklin Resources first reported a position in KALV in Q2 2015 and held it in 13 quarters. The position peaked at $34.9M in Q2 2021. 91 funds tracked by Wall St. Rank hold KALV as of Q2 2022.

Franklin Resources reported no remaining KalVista Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Franklin Resources sold 1,239,731 KalVista Pharmaceuticals shares in Q2 2022, an estimated $18.3M.
Franklin Resources first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 13 quarters.
Franklin Resources's KalVista Pharmaceuticals position peaked at $34.9M in Q2 2021.
91 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2022.

Based on Franklin Resources's 13F filing for Q2 2022, filed 11 Aug 2022.